TherapeuticsMD Q1 2026 net income $103K, license revenue up 84% YoY

TherapeuticsMD, Inc.

2026-Q1 EPS reported $0.01 revenue$724,000

Net income from continuing operations of $103K vs net loss of $636K in Q1 2025.
License revenue $724K, up 84% YoY, primarily from Mayne License Agreement.
Total operating expenses $1.45M, down 13.6% from $1.67M in prior year.
Cash and cash equivalents $8.4M as of March 31, 2026.
Company continues to evaluate strategic alternatives including M&A or sale of assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.